Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects
Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. | NeuroImage | 1 August 2019
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants
Sessa, B., Sakal, C., O’Brien, S., & Nutt, D. | BMJ Case Reports CP | 15 July 2019
Carhart-Harris, R. L., & Friston, K. J. | Pharmacological reviews | 20 June 2019
Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Dowling, G., ... & Halberstadt, A. L. | Drug testing and analysis | 18 June 2018
Bershad, A. K., Schepers, S. T., Bremmer, M. P., Lee, R., & de Wit, H. | Biological Psychiatry | 3 June 2019
‘Never drop without your significant other, cause that way lies ruin’: The boundary work of couples who use MDMA together.
Anderson, K., Reavey, P., & Boden, Z. | International Journal of Drug Policy | 3 June 2019